ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1308

Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD):a Single Center Study of 47 Patients

Madiha Tariq1, Sunny Patel1, Sarwat Umer2, Gloria Caldito3 and Samina Hayat4, 1Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA, 2LSU Health Shreveport, Shreveport, LA, 3Neurology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, 4Rheumatology/Internal Medicine, Louisiana State University Health Sciences Center, Shreveport, Shreveport, LA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Connective tissue diseases, interstitial lung disease and rituximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Interstitial lung disease (ILD) is a fatal complication of connective tissue diseases (CTDs). Despite numerous advances in immunosuppressive agents, data on effective treatment for this challenging entity is limited. This study aims to evaluate the efficacy of rituximab (RTX) in patients with CTD-ILD and determine factors correlated with outcomes at 6, 12 and 24 months post-RTX.

Methods:

We studied 47 patients with CTD-ILD, who met ACR classification criteria for a specific CTD. ILD was confirmed by high-resolution CT chest (HRCT) and pulmonary function tests with forced vital capacity (FVC) and diffusion capacity of lung for carbon monoxide (DLCO). We compared HRCT chest findings, %FVC and %DLCO at time of diagnosis and at 6, 12 and 24 months post-RTX. At diagnosis HRCT chest findings classified into 3 groups (mild, moderate, severe). At 6, 12 and 24 months after RTX, using the same semi-quantitative scoring system, HRCT chest findings were ranked as worsening, stable or improving.

Multiple patient characteristics (Table 1) were tested for their correlation with each outcome. For some variables, nonparametric statistical methods were used due to a small number of non-missing variables. The Spearman rank correlation and Wilcoxon signed rank test were used to determine % change in FVC and DLCO at 6, 12 and 24 months after RTX treatment.

Table 1

Results:

Table 2

1. Most patients were female and African American with median age of 60.

2. HRCT Chest findings after RTX showed either improvement or stability at 6, 12, 24 months (96.3%, 94.7%, and 100% respectively).

3. Given multiple missing variables, there was no statistical difference for changes in FVC and DLCO, however observed changes improved with the median %change ranging from 1 to 3.5. The largest changes were observed for FVC and DLCO at 1 year and DLCO at 2 years after treatment (12.7%, 7.1% and 6.9%, respectively) (table 2).

4. CTD duration showed negative correlation with FVC change at 1 year post-RTX with estimated 1.1% decrease in FVC for every year increase in CTD. ILD duration showed negative correlation with DLCO change at 2 years post-RTX with estimated 3.9% decrease in DLCO for every year increase in ILD.

Conclusion:

RTX is an effective therapy for CTD-ILD. Our study suggests that using RTX earlier in the disease course may have long-term positive impact. RTX may help fill an unmet therapeutic need for CTD-ILD but larger randomized clinical trials are needed.


Disclosure: M. Tariq, None; S. Patel, None; S. Umer, None; G. Caldito, None; S. Hayat, None.

To cite this abstract in AMA style:

Tariq M, Patel S, Umer S, Caldito G, Hayat S. Efficacy of Rituximab for Connective Tissue Disease (CTD) Associated Interstitial Lung Disease (ILD):a Single Center Study of 47 Patients [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/efficacy-of-rituximab-for-connective-tissue-disease-ctd-associated-interstitial-lung-disease-ilda-single-center-study-of-47-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-rituximab-for-connective-tissue-disease-ctd-associated-interstitial-lung-disease-ilda-single-center-study-of-47-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology